All In Biotech

Drug Trial Radar · NCT00403767

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

A Prospective, Randomized, Double-Blind, Parallel-Group, Multicenter, Non-inferiority Study Comparing the Efficacy and Safety of Rivaroxaban (BAY 59-7939) With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation

Last checked: Nov 19, 2026Latest source record: Apr 29, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 14,269 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

14,269

Actual

Start

Dec 2006

Primary completion

Sep 2010

Study completion Sep 2010

Sponsor

Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
Bayer
First posted
Nov 27, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and safety of rivaroxaban with warfarin for the prevention of blood clots in the brain (referred to as stroke) and blood clots in other parts of the body referred to as non-central nervous system systemic embolism) in patients with non-valvular atrial fibrillation (a heart rhythm disorder).

Conditions

  • Atrial Fibrillation
  • Stroke
  • Embolism

Interventions

  • RivaroxabanDrug

    Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One 20 mg tablet once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years (Patients with moderate renal impairment at screening willl have a dose adaptation to rivaroxaban 15 mg, orally, once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years)

  • WarfarinDrug

    Type=exact number, unit=mg, number=1, 2.5, or 5 mg, form=tablet, route=oral use. Number of warfarin tablets to be determined based on target INR values once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years

  • Matching placebo for Rivaroxaban arm (Warfarin placebo)Drug

    Form=tablet, route=oral. One warfarin placebo tablet taken orally once daily for up to an expected maximum treatment period of 32 months that may extend up to 4 years

  • Matching placebo for Warfarin arm (Rivaroxaban placebo)Drug

    Form-tablet, Route=oral administration. Number of rivaroxaban placebo determined by the number of warfarin tablets taken. Duration of treatment is up to an expected maximum treatment period of 32 months that may extend up to 4 years

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Composite Event of Stroke/Non-CNS Systemic Embolism: Primary Efficacy (Non-Inferiority)Time frame: Up to 4 years
  2. The Composite of Event of Stroke/Non-CNS Systemic Embolism: Primary Efficacy (Superiority)Time frame: Up to 4 years
  3. The Composite Event of Major/Non-major Clinically Relevant Bleeding Events: Primary SafetyTime frame: Up to 4 years

Locations

932 sites in 44 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Dothan, Alabama

  • Site not named

    Geneva, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Pell City, Alabama

  • Site not named

    Glendale, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Fort Smith, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Anaheim, California

  • Site not named

    Bakersfield, California

  • Site not named

    Carmichael, California

  • Site not named

    Corona, California

  • Site not named

    Fair Oaks, California

  • Site not named

    Glendale, California

  • Site not named

    Healdsburg, California

  • Site not named

    Laguna Hills, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Gatos, California

  • Site not named

    Mission Viejo, California

  • Site not named

    Modesto, California

  • Site not named

    Mountain View, California

  • Site not named

    Northridge, California

  • Site not named

    Oakland, California

  • Site not named

    Orange, California

  • Site not named

    Pismo Beach, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    San Leandro, California

  • Site not named

    Santa Clara, California

  • Site not named

    Santa Monica, California

  • Site not named

    Santa Rosa, California

  • Site not named

    Sylmar, California

  • Site not named

    Torrance, California

  • Site not named

    Ventura, California

  • Site not named

    Yuba City, California

  • Site not named

    Boulder, Colorado

Showing 40 of 932 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.